Amorphous calcium carbonate

Drug Profile

Amorphous calcium carbonate

Alternative Names: ACC

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amorphical
  • Class Calcium supplements
  • Mechanism of Action Bone development modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hypoparathyroidism
  • Preclinical Bone metastases

Most Recent Events

  • 22 Feb 2017 Amorphical plans a phase I trial for Solid malignancies (NCT03057314)
  • 29 Sep 2016 Pharmacodynamics data from preclinical study in hypoparathyroidism released by Amorphical before 2015(Amorphical pipeline, September 2016)
  • 29 Sep 2016 Amorphical completes a phase I/II trial in hypoparathyroidism in Israel before 2015 (Amorphical pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top